Search
site map
IP Handbook Blog
Your source for expert commentary on IP management issues.
Go to the blog
About
MIHR
PIPRA
Fiocruz, Brazil
bioDevelopments- Institute
|
FEINDT, Hans H
Hans Feindt currently supervises the Monitoring and Enforcement Branch of the Division of Technology Development and Transfer in the NIH Office of Technology Transfer (OTT). He has been with OTT since November 2002. Before joining NIH, he worked in various roles as a scientist, project leader, and research director in the medical diagnostics industry at a number of large and small U.S. companies. During his 20-year industry career, he was employed by Bethesda Research Laboratories, Becton Dickinson & Co., Quidel Corporation, and OraSure Technologies. He contributed to the development and commercialization of rapid, antibody-based tests for a variety of important infectious disease agents. Some of these tests are still in commercial use. In addition to developing new products, he also transferred and established new technologies that were obtained through licensing or acquisition deals by the companies where he was employed. He is listed as a co-inventor on numerous patents and a co-author on a number of scientific publications. Dr. Feindt earned a Ph.D. in biochemistry from Brandeis University and a B.S. in chemistry from the University of Delaware. He and his family currently reside in Baltimore, Maryland.
 Abstract
Administration of Technology Licenses
Abstract:
The National Institutes of Health Office of Technology Transfer (NIH OTT) administers technology licenses for the NIH, generating substantial royalties (in the millions of dollars). Although this revenue flow is important, the NIH OTTs principal mission is the timely introduction of new products and technologies into the marketplace to ensure that the fruits of NIH research and development are made commercially available to serve the greater public good. The NIH OTT utilizes six types of technology licenses:
- commercial evaluation licenses (also known as options)
- patent commercialization licenses (either exclusive or nonexclusive)
- nonexclusive patent licenses (for internal use)
- biological materials licenses
- software licenses
The NIH OTT insists that licenses are drafted with well-defined financial terms and clearly delineated reporting obligations, so that both parties to the license (NIH as licensor and, for example, a biotech firm as licensee) understand their respective obligations. The NIH OTT seeks to build cooperative relationships with its licensees in order to facilitate problem solving discussions, resolve outstanding issues, and identify possible opportunities for advancing commercialization of products and/or services. As a best practices licensor, the NIH OTT carefully manages license administration by monitoring commercial development performance benchmarks, reviewing sales reports, and enforcing other license obligations. The office will also, if necessary, impose sanctions in license enforcement and implement procedures for dealing with infringement of its patents. The policies, protocols, and procedures of the NIH OTT have broad applicability to both developed and developing countries; scientists, administrators, technology managers, intellectual property professionals, and even attorneys can learn from the NIH OTT, a good example of an office operating effectively, efficiently, and profitably by employing best practices.
|
Printer Friendly
Show All Abstracts